美國

證券交易委員會

華盛頓特區20549

表格 10-K/A

修正案一

☒根據1934年證券交易法第13或第15節的年度報告d1934年證券交易法第13或第15節下的報告書

截至財年結束2024年6月30日

☐根據1934年證券交易所法第13或第15節的報告d1934年證券交易法第13或第15節的報告

在過渡期間

委員會檔案編號 001-38758

+1 (305) 918-1980

根據交易所法規（17 CFR 240.14a-12）第14a-12規定的招股材料

根據法案第12(b)節註冊的證券:

根據該法案第12(g)部分登記的證券: 沒有

如果申報人符合《證券法》第405條規定的知名老練發行人，請用複選標記表示。☐是 ☒否

如果申報人不需要根據本法案第13條或第15(d)條提交報告，請用勾選標記表示。 ☐ 是 ☒ 否

指示在復交易所法第13或15(d)條要求的所有報告，在 過去12個月內進行了報告（或對於註冊必須提交此類報告的較短時期），並且（2）已經受到了 過去90天的此類提交要求。是 ☒ 否 ☐

請通過勾選表示，報告人是否在過去12個月內（或報告人被要求提交此類文件的較短期間）按照S-t規則（本章第232.405條）的要求提交了每一個交互式數據文件。是 ☒ 否 ☐

請勾選以下選項以確認該註冊申請人是否爲大型快速提交者、快速提交者、非加速提交者、小型報告公司或新興成長型公司。請參閱交易所法規120億.2中「大型快速提交者」、「快速提交者」、「小型報告公司」和「新興成長型公司」的定義。

如果公司是新興成長型公司，請在選中的方框內打勾，以表示公司已選擇不使用根據交易法第13(a)條規定提供的任何新的或修訂的財務會計準則的延長過渡期來符合這些新的或修訂的財務會計準則。 ☐

請在表示註冊申請人是否提交了公司的管理層針對其財務報告內部控制有效性進行評估的報告和陳述的複選框上打勾，該控制由具備註冊公共會計師資格的會計師事務所或發行其審計報告的公共會計師事務所進行審計，根據薩班斯 - 奧克斯利法(15U.S.C.7262(b))。☐

如果證券根據證券法案第12(b)條註冊，請在複選框中標明，註冊人所提交的財務報表是否反映了以前發佈的財務報表的更正。 ☐

 ☐  

請在複選框中標明，註冊人是否爲殼公司（如《法案規則》第120億.2條所定義）。 ☐是☒不

2023年12月31日，非關聯方持有的投票權和非投票權普通股的總市值爲57,193,356美元。

截至2024年10月27日，註冊人普通股的流通股數量爲161,717,342股，每股面值爲$0.0001（「普通股」）。

通過引用我們向SEC提交的信息，SEC使我們可以引用這些備案文件向您披露重要信息。我們之前向SEC提交了以下文件，並將其通過引用併入本招股說明書中:

無。

說明：

Renovaro公司（以下簡稱「註冊人」，及其全部擁有的子公司，Renovaro生物科學，Renovaro生物科學丹麥ApS，Renovaro Technologies，Inc和Renovaro Cube。 Renovaro國際有限公司（以下簡稱「Renovaro Cube」）。 Renovaro Cube指Renovaro Cube國際有限公司及其全部擁有的子公司GediCube億.V.和Grace系統b.V.（以下簡稱「公司」，「我們」，「我們」或「我們的」）根據1934年修訂版《交易所法》（以下簡稱「交易所法」）編號120億.15規則的要求，只是爲了包括《表格10-K/A第1修正案》（以下簡稱「修正案」）至其截至2024年6月30日的財政年度的年度報告的部分III（項目10到14）中所需的信息，該信息最初於2024年10月10日向美國證券交易委員會（以下簡稱「SEC」）報告。此外，我們修訂了第IV部分的項目15，（i）包括附件97.1，即註冊人的追索政策，因行政錯誤未附在原始提交中，（ii）根據2002年修訂版《薩班斯-奧克斯利法案》第302條的要求，根據《證券交易法》修訂的規則120億.15，包括首席執行官和致富金融（臨時代碼）的新認證。

除非特別描述 以上，原始備案未進行其他更改。爲了保持原始備案中的揭示性質和特徵，在本修正案中未經特別討論的情況下，未對在原始備案後發生的事件的這些披露進行修改或更新。因此，應同時閱讀本修正案及公司向SEC提交的後續備案。除此之外，在原始備案中所做的前瞻性聲明未經修改以反映在原始備案提交後我們了解到的事件，並應當在其歷史背景下閱讀。

第三部分

項目10。董事、高管和公司治理

董事的鑑定

以下是每位董事的業務經驗、資格、技能和教育背景描述，包括每位董事相關的業務經驗:

大衛·韋恩斯坦

於2024年10月14日，本公司董事會任命64歲的David Weinstein為本公司的首席執行官兼董事會成員。在加入本公司之前，Weinstein先生是Dawson James Securities, Inc.的投資銀行業務管理合夥人，自2005年開始在該公司工作。在Dawson James期間，Weinstein先生直接為小型生物科技和醫療保健公司籌集了超過30000萬美元的投資。他還主導了兩家個性化癌症診斷醫療公司的合併，並協助其在納斯達克上市。Weinstein先生畢業於聖約翰學院獲得文學士學位，並在馬里蘭大學獲得公共管理碩士學位。

Maurice 范蒂爾堡

Maurice van Tilburg在金融服務行業和科技企業擔任過多個高級職位，結合了總經理職責、科技、運營服務交付、財務管理、審計和產品開發。他也是一位屢獲殊榮的藝術家，將在行業中的領導職務與成功系列藝術概念相結合。van Tilburg先生目前擔任荷蘭國家成長基金的董事，他在這裡監督著該領域最大的政府投資，致力於創新和科技。通過這一點，他在Techleap.nl的角色上建立了荷蘭科技企業的新的和額外資金來源，以應對全球挑戰、經濟增長以及荷蘭的科技能力和就業。van Tilburg先生將融入他作為Euronext阿姆斯特丹首席執行官的經驗，他負責客戶、產品開發、組織和荷蘭市場的盈利和虧損，以及管理Euronext所有歐洲股票市場的運行。van Tilburg先生的抱負是領導擁有明確使命和積極影響力的團隊，發揮他在金融和藝術領域的領導技能和經驗。在這一背景下，van Tilburg先生還擔任過幾家初創公司的非執行/諮詢董事會成員。

James A. McNulty

麥克諾爾蒂先生擔任MIRALOGX, LLC的CFO，該公司是一家私營育成中心，專注於開發和授權藥品知識產權給私人與公共實體。麥克諾爾蒂先生目前是Inhibitor Therapeutics, Inc.（OTCQB:INTI）的臨時CFO，他自2022年起擔任該職。在1998年離開30年來在坦帕創立三家會計師事務所的公共會計工作後，他擔任過生物製藥行業的CFO，包括在Star Scientific, Inc.（NASDAQ:STSI）工作3年以及在BioDelivery Sciences International, Inc（NASDAQ:BDSI）工作15年。麥克諾爾蒂先生是 MYMD Pharmaceuticals, Inc.（NASDAQ:TNFA）自2014年創立直至2020年初公開前的CEO。他還擔任過 MIRA Pharmaceuticals, Inc.自2020年成立直至2023年底公開、以及 Telomir Pharmaceuticals, Inc.（NASDAQ:TELO）從2021年成立直至2023年公開前的CFO。他在 CV Sciences, Inc（OTC:CVSI）董事會擔任領導董事/審計委員會主席長達五年。他在私營公司擁有豐富經驗，包括擔任 Quantum Technology Sciences, Inc. 董事長五年，直至其被公共公司收購，以及2000年以來擔任 Hopkins Capital Group 的CFO，一個負責業務發展的有限責任公司聯盟，主要從事藥品開發領域的創業活動，同時也是私人公司 Defender Pharmaceuticals, Inc. 的CFO。他是 Perfect Golf Event, LLC 的合夥人，該公司是一家每年組織超過4,000場慈善高爾夫活動的在線平台。他與派特·薩默爾共同撰寫並出版了《業務高爾夫，運用高爾夫球場建立人際關係》。麥克諾爾蒂先生在會計、諮詢/法庭鑑定方面的專業服務包括作為註冊會計師提供專家證詞，主要是在施工訴訟和人身傷害案件中。他於1972年畢業於南佛羅里達州立大學。

道格拉斯·W·卡爾德

自2015年起，Calder先生一直擔任Vycellix, Inc及其附屬公司和聯屬公司的董事長兼董事。他還自2023年4月起擔任納斯達克（NASDAQ：ZVRA）上Zevra Therapeutics, Inc.的董事會成員；自2019年6月以來擔任NextGenNk的董事會成員；自2019年1月以來擔任BioFlorida的董事會成員，以及自2018年7月以來擔任Society for Natural Immunity的成員。Calder先生在生命科學高管方面擁有超過30年的經驗，曾在為總部設在佛羅里達的生物技術公司和研究機構擔任各種高級執行職位，包括Viragen、Accentia Biopharmaceuticals、Biovest International和佛羅里達疫苗與基因治療研究院。同時，他曾在紐約證交所成員公司Gruntal & Co.和Dean Witter Reynolds擔任註冊金融投資組合經理，專注於生命科學股票。Calder先生畢業於佛羅里達州立大學，獲得文學士學位。

Mark A. Collins, 博士

        柯林斯博士已將他長達40年的職業生涯致力於利用電腦進行藥物發現，融合生物學、人工智能和軟體。他在生物科技初創公司、大型製藥公司和科技公司中擔任重要角色，帶領多家公司成功退出。柯林斯博士目前是UndauntedBio公司的首席科學官，自2022年起擔任這一職務，該公司採用獨特的AI驅動臨床知情、網絡醫學方法重新利用現有藥物用於急性和慢性神經病症狀。在那之前，柯林斯博士曾是Icometrix的副總裁轉譯服務，他領導制訂策略推動採用AI輔助MRI和互聯網醫療工具，幫助製藥公司改善中樞神經系統療法在多發性硬化、阿爾茨海默病和帕金森病等多種神經退行性疾病的轉化成功率。在Icometrix之前，從2017年到2021年，柯林斯博士在Helomics, corp.，最近擔任首席技術官，推動AI驅動的腫瘤藥物作用預測模型和臨床結果進入研究和臨床決策支援市場的商業實現和市場推廣。柯林斯博士也是Purplebio Consulting, LLC的創始人和首席顧問，這是一家生命科學顧問公司，提供科學、市場和產品策略諮詢以及實戰執行。柯林斯博士獲得了吉爾福德大學的微生物學哲學博士學位和沃爾特漢普頓大學應用科學學士學位。

家庭關係

我們的執行官或董事之間不存在根據S-k法規第401項(d)款所定義的家庭關係。

涉及某些法律程序

沒有任何審理案涉及到我們公司有利的董事、執行長或該等董事或執行長的任何聯繫人，或有嚴重利益對我們公司不利。

董事會與董事會委員會

董事會. 董事會在2024財政年度召開了十五次會議，並且通過書面同意方式進行。這些會議是定期安排的會議，並且根據需要召開了其他特別董事會會議和電話會議。在2024財政年度，每位現任董事出席了75％或更多董事會會議，以對應每位董事任職期間的時間。董事並不需要出席我們股東的年度大會。

稽核委員會和審計委員會財務專家

稽核委員會已按照1934年修訂後的證券交易所法第10A-3(b)(1)條的規定組織，以及納斯達克的上市標準，並且稽核委員會的每位成員和前成員均符合該等規定和標準。稽核委員會成員分別為詹姆斯·麥克納爾提（主席）、道格拉斯·卡爾德和馬克·科林斯。

審計委員會監督並向我們的董事會匯報各項審計和會計相關事項，包括維護我們基本報表、報告流程和內部控制的完整性；獨立註冊會計師事務所的選擇、評估、薪酬和留任；法律和監管遵循，包括我們的披露控制和程序；以及監督我們的風險管理政策和程序。審計委員會每年指定和設定獨立註冊會計師事務所的薪酬，並審查和評估該審計師。這家外部審計師直接向審計委員會匯報。審計委員會制定有關現任和前任合作夥伴以及外部審計師員工的聘用政策。此外，審計委員會預先批准外部審計師進行的所有審計和非審計服務，以及任何參與與公司財務報告相關工作的外部顧問。審計委員會有直接責任監督為準備或發行審計報告或執行其他審計、審查或證券服務而聘用的外部審計師的工作，包括解決外部審計師和管理層之間的分歧。審計委員會每個財政季度至少開會一次，以履行其憑證下的責任，並與審查公司季度和年度基本報表的相關工作相連。

董事會已確定審計委員會的每位成員具備適當的財務理解和特定行業知識，能夠履行該職位的職責，並且他們在財務方面有足夠的識字能力，並具備納斯達克適用上市標準所要求的相應金融專業水平。董事會已確定詹姆斯·麥克諾爾蒂符合適用SEC和納斯達克規則所定義的「審計委員會財務專家」。

審核委員會在2024財政年度開會六次，在委員任期內出席會議75％或更多，並且委員會也通過書面同意進行操作。 審核委員會根據我們董事會採納的章程運作，並在我們的網站www.renovarogroup.com上公布。

提名及企業管治委員會

提名和企業治理委員會成員包括Maurice van Tilburg和Douglas Calder。

提名和公司治理委員會根據其憑證，負責與理事會的任命和/或選舉相關的事項。包括確定、辨識和推薦潛在候選人以擔任董事會成員，制定標準以考慮公司股東的推薦。提名和公司治理委員會考慮並就所有董事的獨立性提出建議。

提名和企業治理委員會還負責遵守交易所法案和納斯達克的上市標準下的相關企業治理要求。提名和企業治理委員會監督董事會的評估，包括企業治理方面，並制定並向董事會推薦企業治理準則。

提名和公司治理委員會在2024財政年度開會一次，該委員會也有書面同意書。提名和公司治理委員會根據我們董事會通過的憑證運作，並且可在我們的網站www.renovarogroup.com上查看。

董事会薪酬委员会

賠償委員會的成員是詹姆斯 麥克奈爾蒂和道格拉斯·卡爾德。

薪酬委員會根據其憑證允許的規定，負責協助董事會履行其與人力資源和薪酬相關事項的責任，包括股權薪酬，並建立一個供資深管理層連續性和發展計劃。薪酬委員會會定期評估我們執行長的薪酬與同等規模、行業和複雜性的公司進行比較，考慮公司及其他公司的表現。對於我們首席執行官的薪酬所有決定僅由薪酬委員會確定並批准。對於其他執行董事的薪酬，包括激勵獎酬和股權計劃的所有決定首先經薪酬委員會批准，然後與薪酬委員會的建議一起提交給董事會成員最終批准。此外，薪酬委員會將在適當的時候查閱並批准相關與薪酬有關的公開或監管披露，包括薪酬披露與分析，以及任何績效衡量指標。薪酬委員會有權保留並按其認為必要以執行其職責並與公司2024財政年度薪酬相關的任何外部顧問及聘請此類顧問。

董事會已經確定每位薪酬委員會成員均為“非僱員董事”，根據交易所法160億3條的定義，而且也是根據財政部法規第1.162-27(e)(3)條的定義為“外部董事”。薪酬委員會定期會議，並至少在每個財政年度決定管理層的薪酬。

薪酬委員會在2023財政年度期間未召開會議，但通過書面同意進行了行動。薪酬委員會遵照我們董事會採納的憲章運作，在我們的網站www.renovarogroup.com上公佈。

董事會已考慮公司對所有員工的薪酬可能引發的潛在風險，並且認為這些薪酬做法所帶來的風險不太可能對公司產生重大不利影響。

Executive Officers Who Are Not Directors

Simon Tarsh

On March 11, 2024, the Company appointed Simon Tarsh, age 63, as Interim Chief Financial Officer of the Company. Mr. Tarsh most recently served at Deloitte Consulting LLP (“Deloitte”), where he was last a Senior Managing Director in the Finance and Enterprise Performance Practice, and served global clients since 2007. He led a growing global practice focused around operational transformation, including supporting carve out transactions, joint ventures and hybrid structures, both in the US and in international locations, such as India, China, Eastern Europe and Latin America. He supported high growth companies with their finance operations as they globalized, and was able to advise them on their expansion, while balancing growth with appropriate controls. Mr. Tarsh received a Bachelor of Science undergraduate degree in Business and Administration from the University of Salford, Manchester, UK and an MBA from City University Business School, London, UK. He is a Fellow of the Chartered Institute of Management Accountants (1984), which is considered as a CPA equivalent. Mr. Tarsh’s deep financial experience over the length of his career offers valuable insights to our Company, particularly given the enhanced accounting rules and regulations affecting public companies. Since leaving Deloitte, Mr. Tarsh has been providing consulting services through his consulting company, Tarsh PB Advisors LLC (“Tarsh PB Advisors”). Mr. Tarsh is presently a member of the board of directors and chair of the audit committee of Onconetix, Inc. (NASDAQ: BWV).

François Binette

The Company appointed Francois Binette PhD, age 60, as Chief Operating Officer of the Company on November 1, 2022. Dr. Binette has over 25 years of product development expertise in advanced therapies and regenerative medicine. From 2016 to just prior to joining the Company, Dr. Binette was at Lineage Cell Therapeutics, Inc (NYSE:LCTX), a leading company in the field of pluripotent stem cell therapy development with a global footprint focused on ophthalmology, cancer vaccines, and spinal cord injuries, where he served as the Senior Vice President R&D, Global Head of Product Development and led the CNS franchise as well as general pipeline development, contributing to one of the largest non-cancer cell therapy corporate partnership deals with Genentech worth over $650 million in upfront and milestone payments. During his first industry appointment at Genzyme Tissue Repair in Cambridge, he helped pioneer Carticel™ for cartilage repair, the first FDA BLA-approved cell therapy product for human use. He then led R&D for Biosyntech, a startup biomaterials company in Montreal applying its proprietary platform for various tissue engineering and drug delivery applications. Dr. Binette then joined the DePuy Franchise of Johnson and Johnson (NYSE:JNJ), the second largest orthopedic business worldwide where he led several innovative regenerative medicine combination product development initiatives from discovery to approved clinical trials in US and Europe. Dr. Binette received his PhD from Laval University in Québec City, followed with post-doctoral training at the Sanford-Burnham institute, and Harvard Medical School.

Delinquent Section 16(a) Reports

Section 16(a) of the Securities Exchange Act of 1934 requires executive officers, directors and persons who own more than 10% of a registered class of our equity securities to file reports of ownership with the Securities and Exchange Commission. Based solely on our review of the copies of such forms received by us, we believe that during the fiscal year ended June 30, 2024, all filing requirements were timely satisfied, except (i) Avram Miller filed a late Form 3 on November 14, 2023 and a late Form 4 on November 14, 2023; (ii) a late Form 4 filed by Carol Brosgart on February 28, 2024; (iii) a late Form 4 filed by Francois Binette on February 16, 2024; (iv) a late Form 4 filed by Gregg Alton on February 2, 2024; (v) a late Form 4 filed by Henrik Grønfeldt-Sørensen on October 19, 2023; (vi) a late Form 4 filed by James Sapirstein on March 19, 2024; (vii) a late Form 4 filed by Jayne McNicol on May 30, 2024; (viii) Leni Boeren filed a late Form 3 on October 24, 2023 and a late Form 4 on October 25, 2023; (ix) a late Form 4 filed by Luisa Puche on February 16, 2024; (x) a late Form 4 filed by Mark Dybul, M.D. on February 16, 2024; (xi) Ole Abildgaard filed a late Form 3 on October 6, 2023 and a late Form 4 on February 20, 2024; (xii) a late Form 4 filed by René Sindlev on September 12, 2023; and (xvii) Ruud Hendriks filed a late Form 3 on October 24, 2023 and a late Form 4 on October 27, 2023.

Code of Ethics

Our Board has adopted a Code of Ethics and Conduct (our “Code of Ethics”). Our Code of Ethics sets forth standards of conduct applicable to our employees, officers and directors to promote honest and ethical conduct, proper disclosure in our periodic filings, and compliance with applicable laws, rules and regulations. Our Code of Ethics is available to view at our website, www.renovarogroup.com by clicking on Investors/Media-Corporate Governance. We intend to provide disclosure of any amendments or waivers of our Code of Ethics on our website within four business days following the date of the amendment or waiver.

Board Diversity Matrix (As of October 28, 2024)

Item 11. Executive Compensation

 Arrangements with Named Executive Officers

During the fiscal year ended June 30, 2024, we had agreements in place with Dr. Dybul, Mr. Binette, Ms. Puche and Mr. Tarsh. A description of each agreement is set forth below.

Mark R. Dybul, M.D. Since January 7, 2019, when Dr. Dybul became our principal executive officer by virtue of his appointment as Executive Vice-Chair of the Board, Dr. Dybul received compensation as Executive Vice Chair of the Board under his Amended and Restated Director’s Agreement, as amended on May 1, 2019 (the “Director Agreement”), which called for cash compensation of $430,000 per annum, and the grant of options to purchase 300,000 shares of common stock, which was granted on November 21, 2018. The Director Agreement did not provide for any payments or other benefits upon a change in control. Dr. Dybul was given a one-time grant of options to purchase 450,000 shares of common stock at a strike price of $8.00 per share on June 11, 2020.

On October 30, 2019, the Compensation Committee approved and presented to the Board an employment agreement whereby Dr. Dybul would serve as the Company’s Chief Executive Officer (the “Employment Agreement”) which was recommended by the Board for approval by our stockholders. On October 31, 2019, our stockholders approved the Employment Agreement via written consent. Effective July 1, 2021, Dr. Dybul and the Company entered into the Executive Employment Agreement in connection with his appointment to Chief Executive Officer. The Employment Agreement was subsequently amended on December 12, 2022, effective January 1, 2023. The following is a summary of the Employment Terms and other material terms of the Employment Agreement, as amended.

Term. Dr. Dybul would serve as Chief Executive Officer for a term of three (3) years with automatic yearly renewal terms thereafter unless terminated at least 90 days before the expiry of a term.

Duties. Dr. Dybul would perform duties consistent with the position of Chief Executive Officer, as directed by and reporting to the Board, where he would remain a director but without further compensation for Board service. Dr. Dybul would devote a substantial majority of his business time and attention to the performance of his duties with the Company, but he would be able to hold positions with charitable organizations approved by the Board and serve on boards of up to five non-competitive entities, with prior approval by the Board required for publicly traded companies.

Place of Employment and Expenses. Dr. Dybul would work out of the Company’s headquarters in Los Angeles, commuting as needed. Dr. Dybul would be reimbursed for reasonable expenses for accommodations in Los Angeles and a company car.

Cash Compensation. Dr. Dybul would be entitled to a base salary of Five Hundred Fifty Thousand Dollars ($550,000) per year. Dr. Dybul would be eligible for a bonus of up to $800,000 per year in the sole discretion of the Compensation Committee and in accordance with any short-term incentive plan adopted by the Company.

Benefits. Dr. Dybul would receive benefits provided to similarly situated employees of the Company and five (5) weeks’ vacation per year.

Termination. The Employment Agreement could be terminated by the Company for “Cause” or by Dr. Dybul without “Good Reason” (each as defined therein), in which case Dr. Dybul would only receive accrued compensation and benefits. In the event the Company terminates the Employment Agreement without Cause or Dr. Dybul terminates the Agreement with Good Reason, Dr. Dybul would receive his base salary for one (1) year and vesting of one (1) years’ worth of unvested options.

Change in Control. Upon a change in control, the option grant described below would immediately vest, and Dr. Dybul would have the right to terminate the Employment Agreement for Good Reason.

Restrictive Covenants. Dr. Dybul would be subject to restrictive covenants set forth in that certain Confidential and Proprietary Information Agreement attached to the Employment Agreement, which are independent of the obligations set forth in the Employment Agreement. The restrictive covenants include non-compete, non-solicitation and non-disparagement obligations for one (1) year, provided that the Company would continue to pay his base salary for such one (1) year period.

 Description of the Option Grant. Upon appointment to Chief Executive Officer, Dr. Dybul was awarded an option to purchase 3,000,000 shares of the Company’s common stock at an exercise price equivalent to the closing price per share quoted on the NASDAQ Stock Market on the trading day prior to the grant date. The option has a ten-year term, subject to continued employment, and 2,000,000 of the shares will vest ratably on July 1, 2022, July 1, 2023, and July 1, 2024. One-third of the remaining 1,000,000 shares are subject to vesting at the end of each of the three years beginning with the year ending June 30, 2023, based upon the achievement by the Company of certain benchmarks. 333,333 shares that required achievement of certain benchmarks to vest were forfeited as of June 30, 2022, and the remaining balance of 666,667 shares were forfeited as of June 30, 2023.

Francois Binette. Pursuant to his offer letter from the Company, dated February 22, 2022, Mr. Binette was hired as the Company’s Executive VP for Research & Development starting April 2022 with an annual base salary of $375,000, and is eligible for a discretionary cash bonus, with a target of 40% of his base salary. Mr. Binette also received a grant of options to purchase 65,000 shares of Common Stock, vesting on the first anniversary of the date of hire. On October 18, 2022, Mr. Binette was appointed as Chief Operating Officer of the Company, effective November 1, 2022, and pursuant to an amendment to his offer letter, received an increase in base salary to $420,000 and 40,000 options, vesting in equal increments over three years.

Luisa Puche. Pursuant to her offer letter from the Company, dated December 28, 2018 (the “Offer Letter”), Ms. Puche received an annual base salary of $200,000, and was eligible for a discretionary cash bonus, with a target of 40% of her base salary. Ms. Puche also received a grant of options to purchase 60,000 shares of Common Stock and 15,000 restricted stock units, each vesting in equal increments over three years. The Offer Letter provides for at will employment; provided however, that upon termination of Ms. Puche’s employment by the Company without cause, or for a termination of employment by Ms. Puche for good reason, she would receive six months’ salary and COBRA eligibility. Additionally, if the termination without cause or for good reason occurs within 12 months of a change in control, Ms. Puche would also be entitled to a pro-rata bonus and immediate vesting of any unvested options or restricted stock units. Ms. Puche had a base salary of $300,000 for the fiscal year 2022. Effective October 18, 2022, Ms. Puche received an increase in base salary to $350,000 following the completion of the 2022 fiscal year and 80,000 options, vesting in equal increments over three years. Effective March 21, 2024, Ms. Puche resigned from the Company.

Simon Tarsh. Effective March 11, 2024, the Company entered into a consulting agreement (the “Consulting Agreement”) with Tarsh PB Advisors with respect to Mr. Tarsh’s service as the Company’s Interim Chief Financial Officer. Pursuant to the Consulting Agreement, in exchange for Mr. Tarsh’s full-time service as the Company’s Interim Chief Financial Officer, the Company will pay Tarsh PB Advisors $25,000 per month. In addition, Tarsh PB Advisors may be entitled to an additional payment in the amount of up to 30% of the consideration paid under the Consulting Agreement upon the achievement of certain milestones prior to the termination of the Consulting Agreement. In addition, Mr. Tarsh will receive 10,000 stock options that will vest upon the termination date if the Company hires a new CFO prior to such date. The Consulting Agreement has a term of six months from the date of the Agreement and may be renewed for successive one month terms. The Consulting Agreement may be terminated by any party upon thirty days advance written notice.

Outstanding Equity Awards as of June 30, 2024

The following table provides information concerning outstanding equity awards held by our named executive officers as of June 30, 2024.

Board Compensation

The table below sets forth the compensation earned by directors, all of whom are non-employees for services during the fiscal year ended June 30, 2024:

Narrative to Director’s Compensation Table

Our director compensation program reflects competitive practices for a NASDAQ listed company. The resulting compensation package for our directors and for committee service (for non-employee members) as of the date hereof is set forth in the table below. In addition, our directors are awarded annual options to purchase common stock valued at $75,000.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 The following sets forth information regarding the beneficial ownership of our common stock as of October 17, 2024 by:

Beneficial ownership of the Common Stock is determined in accordance with the rules of the SEC and includes any shares of Common Stock over which a person exercises sole or shared voting or investment power, or of which a person has a right to acquire ownership at any time within 60 days. Except as otherwise indicated, we believe that the persons named in this table have sole voting and investment power with respect to all shares of Common Stock held by them. Applicable percentage ownership in the following table is based on 159,066,874 shares of Common Stock outstanding as of October 25, 2024, excluding 3,094,876 shares of Common Stock issuable only upon the exercise of warrants by other warrant holders plus any securities that the individuals included in this table have the right to acquire within 60 days of October 25, 2024.

To our knowledge, except as indicated in the footnotes to this table and pursuant to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all shares of Common Stock beneficially owned by them. Unless indicated otherwise, the address for the beneficial holders is c/o Renovaro Inc. 2080 Century Park E, Suite 906, Los Angeles, CA, U.S.A.

 Equity Incentive Plan Information

The following table provides information, as of June 30, 2024, regarding the number of shares of Company common stock that may be issued pursuant to our 2019 Equity Incentive Plan and 2023 Equity Incentive Plan.

Item 13. Certain Relationships and Related Transactions and Director Independence

Transactions with Related Persons

Advisory Agreement with Avram Miller

On October 10, 2023, Avram Miller, a director, entered into an advisory agreement with the Company (the “Advisory Agreement”), pursuant to which Mr. Miller will provide advice to the Board and the Company on various matters including strategic opportunities, capital allocation, business development, minority investments, licensing arrangements, among others. As compensation for these services, on October 23, 2023, the Company issued Mr. Miller 1,000,000 shares of restricted stock, 166,667 of which will vest in 2024, 444,444 will vest in 2025, and 388,889 will vest in 2026, subject to Mr. Miller’s continued service through each applicable vesting date. On August 23, 2024, Mr. Miller agreed to forfeit the 833,333 unvested shares of restricted stock as consideration for a grant of 978,261 stock options.

Debt Agreements

On February 5, 2024, the Company entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $105,263. The Company received $100,000 in gross proceeds after taking into account the 5% original issue discount. The Note bears an interest rate of 12% per annum and matured on March 1, 2024 . The obligations under this Note are secured by the Amended and Restated Security Agreement. The Company is required to pay interest on the maturity date. For the year ended June 30, 2024, discount amortization of $5,263 was charged to interest expense. As of June 30, 2024, the Company accrued $6,316 of interest expense that is included in accrued expenses on the balance sheet. The Note balance, net of discount at June 30, 2024 is $105,263

On January 2, 2024, the Company entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $526,315 (the “January 2024 Note”). The Company received a total of $500,000 in gross proceeds after taking into account the 5% original issue discount. The January 2024 Note bears an interest rate of 12% per annum and shall mature on March 1, 2024 (the “Maturity Date”) is past due. The Company is required to pay interest on the maturity date. For the year ended June 30, 2024, discount amortization of $26,315 was charged to interest expense. As of June 30, 2024, the Company accrued $31,579 of interest expense that is included in accrued expenses on the balance sheet. The January 2024 Note balance, net of discount at June 30, 2024 is $526,315. In connection with the entry into the January 2024 Note, the Company and Paseco ApS agreed to amend and restate the Security Agreement to add the Company’s obligations under the November 2023 Note and the January 2024 Note to the Secured Obligations (as defined in the Amended and Restated Security Agreement).

On November 3, 2023, the Company entered into an agreement with RS Bio to issue a 5% Original Issue Discount Promissory Note for the principal amount of $1,000,000 (the “November 2023 Note”). The Company received a total of $950,000 in gross proceeds after taking into account the 5% original issue discount. The discount of $50,000 will be accreted over the life of the Note. The Note bears an interest rate of 12% per annum and shall mature on January 1, 2024 (the “Maturity Date”) is past due. The Company is required to pay interest on the maturity date.

Private Placements

On August 1, 2023, RS Bio, purchased in a Private Placement 70,126 of the Company’s Units at a price per Unit equal to $7.13 for aggregate proceeds to the Company of $500,000. The Board of Directors (excluding Mr. Sindlev) approved the participation of certain officers and directors of the Company in the Private Placement on identical terms as the other investors of the Private Placement.

On August 1, 2023, Paseco ApS, in connection with the Private Placement, converted $2,000,000 of its Promissory Note into 280,505 of the Company’s Units at a price per Unit equal to $7.13. In addition, Paseco ApS purchased in the Private Placement 63,114 of the Company’s Units at a price per Unit equal to $7.13 for aggregate proceeds to the Company of $450,000. As a result of participation in the Private Placement, Paseco ApS was deemed to be an affiliate of the Company.

Consulting Agreement with Paseco ApS

The Company currently has a consulting agreement with Paseco ApS for business advisory services since December of 2019. For the years ended June 30, 2023 and 2024 the Company issued zero and 1,000,000 restricted common shares, respectively, as payment for services rendered thereunder.

Compensation of Named Executive Officers and Directors

For information regarding compensation of named executive officers and directors, please see “Item 11. Executive Compensation.”

Except as otherwise indicated herein, there have been no other related party transactions, or any other transactions or relationships required to be disclosed pursuant to Item 404 and Item 407(a) of Regulation S-K.

Director Independence

The NASDAQ listing standards provide that an independent director is one who the Board affirmatively determines is free of any relationship that would interfere with that individual’s exercise of independent judgment. The Board has determined that Mr. van Tillberg, Mr.McNulty, Mr. Calder and Dr. Collins are each independent as defined in the listing standards of NASDAQ. In making such determinations, the Board has concluded that none of these directors has an employment, business, family, or other relationship, which, in the opinion of our Board, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.

Item 14. Principal Accounting Fees and Services

The following information sets forth fees billed to us by Sadler, Gibb & Associates, LLC (“Sadler”) for the years ended June 30, 2024, and June 30, 2023, for (i) services rendered for the audit of our annual financial statements and the review of our quarterly financial statements (“Audit Fees”), (ii) services that were reasonably related to the performance of the audit or review of our financial statements and that are not reported as Audit Fees (“Audit-Related Fees”), (iii) services rendered in connection with tax compliance, tax advice and tax planning (“Tax Fees”), and (iv) services rendered by Sadler other than the foregoing (“Other Fees”).

Audit Fees

For the fiscal year ended June 30, 2024, Sadler billed an aggregate of $271,837 in Audit Fees. For the fiscal year ended June 30, 2023, Sadler billed an aggregate of $170,000 in Audit Fees.

Audit-Related Fees

For the fiscal year ended June 30, 2024, Sadler billed an aggregate of $28,000 in Audit-Related Fees. For the fiscal year ended June 30, 2023, Sadler billed an aggregate of $1,500 in Audit-Related Fees.

Tax and Other Fees

None.

Audit Committee’s Pre-Approval Process

The Audit Committee, which has been in place since March 28, 2018, pre-approves all audit and permissible non-audit services on a case-by-case basis. In its review of non-audit services, the Audit Committee considers whether the engagement could compromise the independence of our independent registered public accounting firm, and whether it is in our best interests to engage our independent registered public accounting firm to perform the services. The Audit Committee does not delegate its responsibilities to pre-approve services performed by our independent registered public accounting firm to management. The Audit Committee may delegate, and has delegated, pre-approval authority to one or more of its members. The member or members to whom such authority is delegated must report any pre-approval decisions to the Audit Committee at its next scheduled meeting.

During the year ended June 30, 2024, all services performed by Sadler were pre-approved by the Audit Committee.

Item 15. Exhibits and Financial Statement Schedules

ITEM 16. FORM 10-K SUMMARY

Not Applicable.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

17